-
Je něco špatně v tomto záznamu ?
β-glucan as a new tool in vaccine development
V. Vetvicka, L. Vannucci, P. Sima,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy
Grantová podpora
61388971
Institutional grants RVO
ARPA Foundation
Institutional grants RVO
Unicredit Bank
Institutional grants RVO
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1972-01-01 do Před 1 rokem
Wiley Free Content
od 1997 do Před 1 rokem
PubMed
31544248
DOI
10.1111/sji.12833
Knihovny.cz E-zdroje
- MeSH
- adjuvancia imunologická * MeSH
- beta-glukany imunologie terapeutické užití MeSH
- hydrogely terapeutické užití MeSH
- lidé MeSH
- oligodeoxyribonukleotidy MeSH
- prezentace antigenu MeSH
- systémy cílené aplikace léků metody MeSH
- vakcinace MeSH
- vakcíny imunologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Vaccination constitutes one of the major breakthroughs in human medicine. At the same time, development of more immunogenic vaccine alternatives to using aluminium-based adjuvants is one of the most important phases of vaccination development. Among different sources of carbohydrate polymers, including plants, microbes and synthetic sources tested, glucans were found to be the most promising vaccine adjuvant, as they alone stimulate various immune reactions including antibody production without any negative side effects. The use of glucan particles as a delivery system is a viable option based on the documented efficient antigen loading and receptor-targeted uptake in antigen-presenting cells. In addition to particles, soluble glucans can be used as novel hydrogels or as direct immunocyte-targeting delivery systems employing novel complexes with oligodeoxynucleotides. This review focuses on recent advances in glucan-based vaccine development from glucan-based conjugates to a glucan-based delivery and adjuvant platform.
Department of Pathology University of Louisville Louisville KY USA
Laboratory of Immunotherapy Institute of Microbiology Prague Czech Republic
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005876
- 003
- CZ-PrNML
- 005
- 20200522090637.0
- 007
- ta
- 008
- 200511s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/sji.12833 $2 doi
- 035 __
- $a (PubMed)31544248
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Vetvicka, Vaclav $u Department of Pathology, University of Louisville, Louisville, KY, USA.
- 245 10
- $a β-glucan as a new tool in vaccine development / $c V. Vetvicka, L. Vannucci, P. Sima,
- 520 9_
- $a Vaccination constitutes one of the major breakthroughs in human medicine. At the same time, development of more immunogenic vaccine alternatives to using aluminium-based adjuvants is one of the most important phases of vaccination development. Among different sources of carbohydrate polymers, including plants, microbes and synthetic sources tested, glucans were found to be the most promising vaccine adjuvant, as they alone stimulate various immune reactions including antibody production without any negative side effects. The use of glucan particles as a delivery system is a viable option based on the documented efficient antigen loading and receptor-targeted uptake in antigen-presenting cells. In addition to particles, soluble glucans can be used as novel hydrogels or as direct immunocyte-targeting delivery systems employing novel complexes with oligodeoxynucleotides. This review focuses on recent advances in glucan-based vaccine development from glucan-based conjugates to a glucan-based delivery and adjuvant platform.
- 650 12
- $a adjuvancia imunologická $7 D000276
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a prezentace antigenu $7 D017951
- 650 _2
- $a systémy cílené aplikace léků $x metody $7 D016503
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrogely $x terapeutické užití $7 D020100
- 650 _2
- $a oligodeoxyribonukleotidy $7 D009838
- 650 _2
- $a vakcinace $7 D014611
- 650 _2
- $a vakcíny $x imunologie $7 D014612
- 650 _2
- $a beta-glukany $x imunologie $x terapeutické užití $7 D047071
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vannucci, Luca $u Laboratory of Immunotherapy, Institute of Microbiology, Prague, Czech Republic.
- 700 1_
- $a Sima, Petr $u Laboratory of Immunotherapy, Institute of Microbiology, Prague, Czech Republic.
- 773 0_
- $w MED00010600 $t Scandinavian journal of immunology $x 1365-3083 $g Roč. 91, č. 2 (2020), s. e12833
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31544248 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200522090635 $b ABA008
- 999 __
- $a ok $b bmc $g 1524734 $s 1095932
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 91 $c 2 $d e12833 $e 20191113 $i 1365-3083 $m Scandinavian journal of immunology $n Scand J Immunol $x MED00010600
- GRA __
- $a 61388971 $p Institutional grants RVO
- GRA __
- $a ARPA Foundation $p Institutional grants RVO
- GRA __
- $a Unicredit Bank $p Institutional grants RVO
- LZP __
- $a Pubmed-20200511